Berenberg analyst Gaurav Goparaju made no change to the firm’s Buy rating or $33 price target on Recursion Pharmaceuticals (RXRX) after the company announced a new collaboration and $50M PIPE from Nvidia (NVDA), which will leverage Recursion’s datasets and Nvidia’s computing capabilities. The firm views Recursion’s ability to leverage its data outside of its drug discovery collaborations as a key differentiator, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RXRX:
- RXRX Stock Spikes after NVIDIA Invests $50M
- Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
- Recursion Pharmaceuticals announces collaboration, $50M investment from NVIDIA
- Recursion Pharmaceuticals management to meet with Piper Sandler
- Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem